See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

UroGen’s Zusduri benefit maintained in NMIBC Phase III study

Summary by Clinical Trials Arena
Urogen's Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.The post UroGen’s Zusduri benefit maintained in NMIBC Phase III study appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Clinical Trials ArenaClinical Trials Arena

UroGen’s Zusduri benefit maintained in NMIBC Phase III study

Urogen's Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.The post UroGen’s Zusduri benefit maintained in NMIBC Phase III study appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Wednesday, August 6, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal